Horizon cell line sequence released in bid to up bioproduction efficiency

By Dan Stanton

- Last updated on GMT

Image: iStock/kasto80
Image: iStock/kasto80

Related tags Cell line Gene Cell culture

Horizon Discovery will allow researchers to modify a genome sequence based on its knock-out CHO K1 cell line in a bid to drive innovation in bioproduction.

Horizon is releasing the sequence as a reference tool for researchers to both screen for genes associated with desired phenotypes and to drive innovation in bioproduction in what the firm said was a rare move by a gene-editing company.

“Releasing the sequence will enable bioproduction researchers both in academia and industry to more easily modify their CHO cells through genome engineering, for example to increase product quality or yield,”​ Jamie Freeman, product manager at the UK-based translational genomics firm told Biopharma-Reporter.

“It is not common to be permitted to modify manufacturing ready cell lines in this manner. Therefore, by releasing the sequence we hope to drive innovation in the field, as well as increase uptake of our cell line.”

He added Horizon’s GS Knockout CHO cell line is widely accessible, with flexible licensing terms, “so we believe that it is logical to use our cells for these experiments, as the released sequence is the most accurate available.”

The project will also help Horizon further enhance the cell line using genome editing approaches, Freeman said. “We will use it to research and identify targets leading to future iterations of the cell line that will be released for commercial manufacturing with improved attributes for bioproduction.”

The sequence was done in collaboration with the Wellcome Trust Sanger Institute, and will be made available publicly via the Ensembl website at EMBL-EBI.

Related news

Show more

Related products

Riding the mRNA Highway

Riding the mRNA Highway

Content provided by Thermo Fisher Scientific - Biosciences | 15-May-2023 | White Paper

Learn more about process development and manufacturing in the mRNA space to enable successful scale-ups of mRNA production for therapeutic applications.

Impurity profiling and analysis of TheraPure GMP nucleotides

Impurity profiling and analysis of TheraPure GMP nucleotides

Content provided by Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | White Paper

Nucleoside triphosphates (NTPs) are vital components of emerging RNA therapeutics and vaccines. Controlling impurities that may be present in them while...

eBook: mRNA prospects and scale-up solutions

eBook: mRNA prospects and scale-up solutions

Content provided by Thermo Fisher Scientific - Biosciences | 22-Mar-2023 | Insight Guide

This mRNA eBook was created by Thermo Fisher Scientific, in collaboration with Genetic Engineering & Biotechnology News (GEN), to provide you with...

Related suppliers

Follow us

Products

View more

Webinars